Forty-one unrelated Japanese patients with heterozygous familial hypercholesterolemia (FH) from the Kanto area (central region) of Japan were screened for mutations in the LDL receptor gene using the polymerase chain reaction (PCR)-restriction enzyme fragment length polymorphism (RFLP) and PCR-heteroduplex analysis methods, followed by sequencing and Southern blotting. Four previously described mutations, 1845+2T->C (by PCR-RFLP), and D412H, K790X and 327insC (by heteroduplex analysis), were positively identified. In 36 (83.7%) of the patients, mutations were not detected, and the detection rate was lower than previously reported from other regions of Japan. Our results suggest that in the Kanto area, a wide variety of the mutations may be associated with FH, and further refinement of this strategy is required to screen effectively for this disease.
INTRODUCTION
Familial hypercholesterolemia (FH) is a common autosomal dominant disorder that is caused by mutations in the low-density lipoprotein receptor (LDL-R) gene, and is characterized by increased plasma levels of low-density lipoprotein cholesterol (LDL-C), xanthoma, atherosclerosis, and premature coronary heart disease (CHD)1). Clinical symptoms develop as cholesterol-rich lipoproteins accumulate in the plasma due to impaired uptake and degradation of LDL by mutant receptors in peripheral cells1). CHD can be prevented in FH patients by administering lipid lowering therapy at early stages of the disease. Therefore, early diagnosis of FH by determination of lipid status and genetic screening is clinically important.
Various molecular defects have been identified within the LDL-R gene, including deletions, insertions, missense mutations and nonsense mutations (http://www.ucl.ac.uk/ fh/), and to date, a total of more than 800 different mutations have been reported worldwide2), 3) . The frequency of heterozygous FH is generally estimated to be 0.2% among the general population3). In Japanese patients, more than 60 mutations have been reported4-7). A limited number of mutations have shown to predominate, and mutations such as 1845+2T->C, K790X and C317S were reported to be common in the Kansai district4), while five different mutations (K790X, P664L, FH-Tonami-1, IVS15-3C>A and FH Tonami-2) were reported to be frequent in individuals of the Hokuriku district5). Based on these reports, it appears that the prevalence of these mutations may vary with regions due to founder effects. However, mutations have not been identified in 30-50% of Japanese FH patients and the familial ligand-defective apoB-100 (FDB), which also causes FH and is common in Europe and North America, is rarely seen in Japan8) Therefore, a strategy for detecting known LDL-R mutations, including those common in Japanese FH. In the present report, we present the results of screening all exons as well as intron 12 for LDL-R mutations and discuss approaches to establish a rapid and clinically effective genetic screening for FH in the Kanto area.
MATERIALS AND METHODS

Patients
Patients were recruited from the Department of Medicine and Gerontology at Kyorin University School of Medicine and from the Ohmiya Medical Center at Jichi Medical School. A total of 41 unrelated FH patients (16 males, 25 females) and 2 (2 females) of their relatives were included in the analysis. FH was diagnosed based on high plasma levels of LDL-C (>200mg/dl, 5.2mmol/L), total cholesterol>260mg/dl, 6.7mmol/L)), Achilles tendon thickness (>10mm by radiologic examination), and positive family history, according to previously reported criteria9). Serum lipid status, including total cholesterol (TC), triglyceride (TG) and high-density lipoprotein cholesterol (HDL-C), was measured by enzymatic methods. LDL-C was calculated according to the Friedewald formula10)
Isolation of genomic DNA Genomic DNA was collected from the buffy coat of peripheral blood as previously described11), and was then suspended in distilled water.
Amplification of genomic DNA The reported primer pairs for 18 exons12) and an introm4) were used. The LDL-R genes of patients were amplified (PCR) with 2.5U DNA polymerase using an automated thermal cycler. The amplification reaction comprised 35 cycles of incubation of the reaction mixture for (1) denatursize fractionated, together with a PCR product from a normal control, by 2% agarose gel electrophoresis. PCR bands for sequencing were isolated from low melting agarose gel and purified using a Prep A Gene kit (Bio-Rad Laboratories, Hercules, CA).
PCR-RFLP
In order to detect mutations in intron 12 (the 1845+2T->C), PCR-restriction enzyme length polymorphism (RFLP) was performed as previously reported4). Briefly, a region fied product was then digested with BsaHI (Toyobo Co. Ltd., Tokyo, Japan). Restriction fragments were then separated on a 3% agarose gel, stained with ethidium bromide and visualized with ultra violet light.
PCR-heteroduplex analysis
Heteroduplex analysis was performed according to the method of Keen13). Briefly, except for exon 12, each of the 17 exon fragments of LDL-R were amplified by PCR.
Twenty microliters of PCR product was then mixed with
Foster City, CA) according to the manual provided by the non-denaturing MDE gel manufacturer (AT Biochem, Malvern, PA). Seven microliters of PCR product was gel (AT Biochem, Malvern, PA) containing 15% urea in 0.5x TBE, and was separated by electrophoresis at 500V for 18h. The homo-and heteroduplexes were visualized by ethidium bromide staining under UV illumination.
Sequencing of genomic DNA Sequencing of PCR products was performed using an AmpliCycle sequencing kit (PE Applied Biosystems, Foster City, CA) and 32P-labeled primers. We sequenced those cases who showed abnormal PCR-heteroduplex or PCR-RFLP.
Southern blotting
Ten micrograms of genomic DNA was digested by 100U of BamHI, separated by 0.8% agarose gel electrophoresis, transferred onto a nylon membrane (Biodyne A, Poll) and fixed by UV crosslinking. Membranes were then subjected to hybridization and autoradiographic detection with 32P-labeled LDL-R cDNA probes for exons 2 to 18 (2.4kb of RT-PCR product of LDL-R mRNA from a human cell line).
RESULTS
Detection of the 1845+2T->C mutation by PCR-RFLP Figure 1 shows the PCR-RFLP results of 5 individuals. PCR products of intron 12 from a normal control after BsaHI digestion gave a single 190-bp band (lane NC). On the other hand, PCR products from a patient (Lane H.H.) yielded two bands (166 by and 190bp), indicating that the mutant allele was heterozygous in this patient. Bands in the rest of the patients (Lane 3-5) were the same as those seen in the normal control (Figure 1 ). However, we identified an other patient (K.K., unrelated to H.H.) who showed same abnormal pattern. (Figure 2, B, lower) . The heteroduplex band of exon 17 of two patients (S.H. and J.M.) was also abnormal (Figure 2, C, upper) . Sequencing of exon 17 from patients S.H. and J.M. showed a single base substitution (A to T) resulting in a stop codon (TGA) in place of lysine (K790X in Figure 2 , C, lower). These results also indicated that the patients were heterozygous for the mutant allele. There were no differences regarding heteroduplex pattern of normal control DNA and that from the other patients. Overall screening results All 43 cases (41 patients and two relatives) were screened for 1845+2T->C by PCR-RFLP, 36 were screened by PCR-heteroduplex analysis of all 18 exons, followed by sequencing of the 4 positive cases, and 16 were screened by southern blotting. Genetic screening positives are shown with lipid profiles in Table 1 (Table 1) .
DISCUSSION
In the present genetic screening of 43 Japanese FH patients from the Kanto area, we identified four previously described mutations, D412H11), K790X4), 1845+2T-> C14,15) and 327insC7), by PCR-RFLP and PCR-heteroduplex analysis followed by direct sequencing, and a single abnormality by Southern blotting in the LDL-R gene. Our results indicated that PCR-heteroduplex analysis of exon17 is useful in screening for K790X. PCR-heteroduplex analysis was also shown to detect D412H and 327insC. In Japan, more than 60 mutations have been reported, and information regarding LDL-R mutations is gradually accumulating. Previously, 120 unrelated FH heterozygotes from the Kansai area were screened for five point mutations (1845+2T->C, C317S15), K790X, P664L12) and E119K12)) that are common in Japanese FH patients4). They included two mutations (K790X and E119K) whose birth place is the Kanto area4). More recently, five mutations (K790X, P664L, FH-Tonami-116), IVS15-3C>A and FH-Tonami-216)), of which two overlapped with the above report, were found to be common in 200 FH patients from the Hokuriku areas). The researchers used PCR denaturing gradient gel electrophoresis (DGGE), DNA sequencing and Southern blotting. Using similar methods, another group reported several common mutations (including 6 unidentified mutations and 3 previously reported mutations; C317S, K790X and 1845+2T->C) in 120 FH patients in the Kanto area6).
Their detection rate of 14/120 (11.6%) in the Kanto area is similar to that of the present study, which had a detective rate of 5/41 (12.2%). These were lower than reported in previous studies by Yu et al. (41.5%) in the Hokuriku area and by Maruyama et al. in the Kansai area (31.7%), and thus the detection rate obtained using our strategy may be less than satisfactory. In Japan, numerous additional mutations, including large deletions, have been reported [17] [18] [19] [20] [21] [22] [23] Another report also indicated a lower prevalence of 7 mutations (different from those we identified) in LDL-R genes from 44 of 101 Japanese FH patients of unknown origins using single-strand conformation polymorphism (SSCP) analysis24). The Japanese are generally believed to be a genetically uniracial population due to their prolonged geographical and political isolation. Because Japanese individuals have been moving to the Kanto area for at least the past 100 years, since the national capital was firmly established in Tokyo (center of Kanto area), a wide variety of mutations, including those originating locally, may be found in this area, and this may decrease the detection rate.
Another explanation is the fact that genetic mutations other than those in LDL-R clinically manifest themselves as conditions similar to FH. Genetic mutations not typical of those commonly observed in FH and that result in FH-like symptoms may remain undetected in our group. Sitosterolemia is such a condition25). This is an FH-like disease that is caused by mutations in two adjacent ATPbinding cassette (ABC) transporters, ABCG5 and ABCG8, and is characterized by elevated plasma plant sterol and cholesterol25). The frequency of sitosterolemia among Japanese FH patients remains unclear. Other candidate diseases include a condition linked to chromosome lp34-32 that is associated with autosomal dominant hypercholesterolemia26). These conditions could not be excluded in our study. However, the familial ligand-defective apoB-100 (FDB), which also causes FH and is common in Europe and Noth America is rarely found in Japan27). The low detection rate in the current study may be due to the fact that numerous LDL-R and related mutations, including common mutations, remain undetected by our strategy. With regard to methodology, the characteristics of the method selected may affect the results of screening29-31) Therefore, targeting of all 6 mutations gov/genome/guide/human/), by using DNASIS-MAC ver.3 (Hitachi software engineering) shows that five DNA fragments (14.9kb, 16kb, 2.2kb, 2kb, 0.1kb) that can bind to the probe for exons 2 to 18, are produced by BamHI digestion of human cDNA, Two of the predicted bands (14.9kb, 16kb) seemed to correspond to a single 10kb band of the normal control yielded in our study. Because the genomic DNA from patient M.H. after BamHI digestion gave an extra 20kb band, it was suggested that any one of BamHI sites between genome No. 32718 and 76075 was deleted in the genome of the patient. Technological innovation may ensure that future screening is reliable and convenient. DNA chips or solution-phase microarrays31 are potential candidates, if cost per sample can become acceptable. In conclusion, we herein presented the results of genetic screening in Japanese FH patients and discussed approaches to establish an effective screening strategy that is applicable to the Kanto area.
